Four scientific leaders who together, shared a vision that there was a lack of therapeutic innovation in treating cardiovascular diseases – the number one cause of death globally, founded MyoKardia in 2012. The firm is pioneering a precision medicine approach to treating cardiomyopathies and other forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
MyoKardia engaged SVA Consulting at the end of its Phase 3 program to evaluate the commercial capabilities of their financial systems. The question at hand was whether MyoKardia should take on the implementation of a new ERP system, or whether their current ERP system would support a commercial company.
SVA considered both the views and perspectives of the stakeholders at MyoKardia as well as consulted on the business processes that would need to be implemented as the company transitioned into a commercially-operating company. SVA then compared the needs of the organization to the current business systems and recommended a fit-for-purpose approach to gaining the required business capabilities, leveraging and building from MyoKardia's current systems.